Dynamic changes in HCV RNA levels and viral quasispecies in a patient with chronic hepatitis C after telaprevir-based treatment

Journal of Clinical Virology

Volumn 53, Issue 2, 2012, Pages 174-177

  De Bruijne, Joep ^a   Sullivan, James C ^b   Kieffer, Tara L ^b   Botfield, Martyn ^b   Shames, Ben ^b   Schinkel, Janke ^a   Molenkamp, Richard ^a   Weegink, Christine ^a   Reesink, Henk ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b VERTEX PHARMACEUTICALS   (United States)

Author keywords

Antiviral treatment; Direct acting antiviral (DAA); Hepatitis c virus; Phylogenetic analysis; Protease inhibitor; Sequence analysis; Telaprevir

Indexed keywords

AMANTADINE; PEGINTERFERON ALPHA2A; RIBAVIRIN; TELAPREVIR; VIRUS RNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CASE REPORT; CAUCASIAN; DRUG MEGADOSE; DRUG WITHDRAWAL; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HLA TYPING; HUMAN; LIVER CIRRHOSIS; MALE; MICROBIAL POPULATION DYNAMICS; PHASE 2 CLINICAL TRIAL; PHYLOGENY; PNEUMOTHORAX; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELAPSE; RNA ISOLATION; SEQUENCE ANALYSIS; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE COUNT; VIRAL CLEARANCE; VIRUS LOAD;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84855535500     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2011.11.004     Document Type: Article

References (15)

1. Lauer G.M., Walker B.D. Hepatitis C virus infection. N Engl J Med 2001, 345:41-52.
2. Bortolotti F., Verucchi G., Cammà C., Cabibbo G., Zancan L., Indolfi G., et al. Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology 2008, 134:1900-1907.
3. Denis J., Rautou P.E., Lambare B., Herbert S., Auray-Cartier V., Asselah T. Chronic hepatitis C: viral clearance several months after discontinuation of therapy in two non-responders. Infection 2007, 35:197-200.
4. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 22:958-965.
5. McHutchison J.G., Lawitz E.J., Shiffman M.L., Muir A.J., Galler G.W., McCone J., et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009, 361:580-593.
6. Reesink H.W., Zeuzem S., Weegink C.J., Forestier N., van V.A., van de Wetering de Rooij J., et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006, 131:997-1002.
7. Lin K., Kwong A.D., Lin C. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells. Antimicrob Agents Chemother 2004, 48:4784-4792.
8. McHutchison J.G., Everson G.T., Gordon S.C., Jacobson I.M., Sulkowski M., Kauffman R., et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009, 360:1827-1838.
9. Hezode C., Forestier N., Dusheiko G., Ferenci P., Pol S., Goeser T., et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009, 360:1839-1850.
10. McHutchison J.G., Manns M.P., Muir A.J., Terrault N.A., Jacobson I.M., Afdhal N.H., et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010, 362:1292-1303.
11. Sarrazin C., Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010, 138:447-462.
12. Kwong AD, Frantz JD, Bartels DJ, Lin C, Shames B, Seepersaud S, et al. Methods for amplifying hepatitis C virus nucleic acids. WO patent 2010090857; August 12, 2010.
13. Neumann-Haefelin C., McKiernan S., Ward S., Viazov S., Spangenberg H.C., Killinger T., et al. Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution. Hepatology 2006, 43:563-572.
14. Farci P., Shimoda A., Coiana A., Diaz G., Peddis G., Melpolder J.C., et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000, 288:339-344.
15. Zeuzem S., Sulkowski M., Zoulim F., Sherman K.E., Alberti A., Wei L.J., et al. Long-term follow-up of patients with chronic hepatitis C treated with telaprevir in combination with peginterferon alfa-2a and ribavirin: interim analysis of the extend study. Hepatology 2010, 52:436.